Shanghai Haohai Biological Technology Co., Ltd. provided preliminary unaudited consolidated group earnings guidance for the year ended 31 December 2023. For the year, the group expects to record a net profit attributable to shareholders of the Company of approximately RMB 400,000,000 to RMB 430,000,000, representing an increase of approximately RMB 219,530,300 to RMB 249,530,300, or approximately 121.64% to 138.27%, as compared to that in 2022 (corresponding period in 2022: audited net profit attributable to shareholders of the Company of RMB 180,469,733.31). The net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss is expected to be approximately RMB 367,000,000 to RMB 397,000,000, representing an increase of approximately RMB 208,250,400 to RMB 238,250,400, or approximately 131.18% to 150.08%, as compared to that in 2022 (corresponding period in 2022: audited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss of RMB 158,749,648.52).
Shanghai Haohai Biological Technology Co., Ltd.
Equities
6826
CNE100001W69
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.55 HKD | +1.47% | +9.34% | +3.10% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+3.10% | 1.98B | |
-2.14% | 187B | |
-2.39% | 106B | |
-4.21% | 66.9B | |
+1.93% | 49.45B | |
+16.82% | 48B | |
+4.06% | 40.84B | |
+3.17% | 26.48B | |
+1.31% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- 6826 Stock
- News Shanghai Haohai Biological Technology Co., Ltd.
- Shanghai Haohai Biological Technology Co., Ltd. Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended 31 December 2023